The present study was designed to investigate the role of mast cells and mast cell-derived
histamine in
vincristine-induced
neuropathic pain.
Neuropathic pain was induced by administration of
vincristine (100 μg/kg, i.p.) over a period of 10 days, with a break of 2 days, and
pain behavioural estimations including pin prick, hot plate and
acetone spray tests were performed to assess mechanical and heat
hyperalgesia and cold
allodynia, respectively, on days 0, 14 and 28.
Mast cell stabilizer,
sodium cromoglycate,
H1 receptor antagonist
promethazine and H2 receptor antagonist
ranitidine were administered over a period of 12 days. Administration of
vincristine resulted in significant development of heat and
mechanical hyperalgesia as well as cold
allodynia. Furthermore, the
pain observed was markedly elevated on the 28th day in comparison to the 14th day. Administration of
sodium cromoglycate,
promethazine and
ranitidine significantly reduced mechanical and heat
hyperalgesia and cold
allodynia. However, the
pain-attenuating effects of
ranitidine were significantly less as compared to
sodium cromoglycate and
promethazine, which suggests that
H1 receptors play a more important role than
H2 receptors in
vincristine-induced
neuropathic pain. It may be concluded that
vincristine may degranulate mast cells to release inflammatory mediators, particularly
histamine which may act through H1 (primarily H1) and
H2 receptors to induce
neuropathic pain.